Dr. Lal Path Labs liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
34.88×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.48×3.48×3.39×2.42×2.07×
3.38×3.38×3.30×2.34×2.00×
665665619475414
1,1161,116961662503
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,040 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————34.88
Current Ratio2.072.423.393.483.48
Quick Ratio2.002.343.303.383.38
Cash, Equiv & ST Investments413.6474.7619.3665.4665.4
Working Capital503.2661.5961.01,115.91,115.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.